Fibromyalgia News and Research

Latest Fibromyalgia News and Research

Pico-Tesla commences placebo-controlled Magneceutical Therapy study for Alzheimer's disease

Pico-Tesla, The Magneceutical Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have Alzheimer's disease symptoms.

6 Jan 2011

Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease

Pico-Tesla, The Magneceutical Company, announced that it has expanded its ongoing Phase III pivotal clinical trial by adding three Principal Investigators, including two university-affiliated clinicians: one in Denver; and one in Tampa.

5 Jan 2011

New study reports close association between obesity and fibromyalgia

Afflicting up to 5 percent of the U.S. population, mostly women, fibromyalgia is characterized by widespread pain and range of function problems. A new study in The Journal of Pain reports there is close association between obesity and disability in fibromyalgia patients.

29 Dec 2010

Ramius/RP Group extend tender offer to acquire Cypress Bioscience

Ramius V&O Acquisition LLC, affiliates of Ramius LLC (collectively, "Ramius") and affiliates of Royalty Pharma (together with Ramius and Purchaser, the "Ramius/RP Group") announced today that the Ramius/RP Group is extending its previously announced tender offer to acquire all of the outstanding shares of common stock of Cypress Bioscience, Inc., a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, until Midnight, January 5, 2011, unless the offer is otherwise extended.

22 Dec 2010

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Chelsea Therapeutics International, Ltd. announced it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated Parkinson's disease, multiple system atrophy and pure autonomic failure.

20 Dec 2010

Adeona expands and enhances zinc-based product candidate portfolio

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has acquired access to clinical data supporting a zinc-based therapy for the prevention of infections in the elderly. This acquisition expands and enhances Adeona's zinc-based product candidate portfolio that already includes its proprietary zinc-based tablets for use in the dietary management of mild to moderate Alzheimer's disease and mild cognitive impairment patients, and age-related macular degeneration.

16 Dec 2010

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Pico-Tesla, The Magneceutical® Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have fibromyalgia. The pilot study seeks to determine whether the application of magnetic fields generated by Pico-Tesla's patented Resonator™ system can be effective as an adjunctive therapy to oral medications in ameliorating the symptoms of fibromyalgia.

16 Dec 2010

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

12 Dec 2010

Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting

New data on UCB's anti-epileptic drug (AED) Vimpat (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Convention Center in San Antonio, Texas from December 3 to 7, 2010. Data will also be presented on Keppra XR and the investigative epilepsy therapy, brivaracetam.

1 Dec 2010

FDA grants Impax tentative approval for generic Cymbalta NDA

Impax Laboratories, Inc. confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application for generic version of Cymbalta® delayed-release (duloxetine hydrochloride) 20, 30 and 60 mg capsules.

22 Nov 2010

Adeona third quarter total net revenues increase to $289,898

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced its third quarter 2010 financial results as well as recent clinical and operational achievements.

15 Nov 2010

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.

12 Nov 2010

TONIX Pharmaceuticals announces Phase 2a study results of cyclobenzaprine in Fibromyalgia Syndrome

TONIX Pharmaceuticals (formerly known as Krele Pharmaceuticals), a specialty central nervous system (CNS) pharmaceutical company, announced results of a new analysis of a Phase 2a study, which previously demonstrated reduced pain, fatigue and tenderness in patients with Fibromyalgia Syndrome (FMS) following bedtime administration of very low dosage (VLD) cyclobenzaprine (CBP).

10 Nov 2010

Tai Chi benefits individuals with arthritis

In the largest study to date of the Arthritis Foundation's Tai Chi program, participants showed improvement in pain, fatigue, stiffness and sense of well-being.

8 Nov 2010

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

The U.S. Food and Drug Administration today approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. Cymbalta was first used to treat major depressive disorder in 2004.

8 Nov 2010

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.

4 Nov 2010

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

Pfizer Inc announced that the Japanese Ministry of Health, Labour and Welfare approved Lyrica (pregabalin) capsules for the treatment of peripheral neuropathic pain. This follows the recent approval in Japan of Lyrica for the treatment of postherpetic neuralgia on April 16, 2010. Lyrica is the first medication approved for peripheral neuropathic pain in Japan where it is co-promoted with Eisai Co., Ltd.

29 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

Study suggests treating RLS may improve sleep and quality of life in people with fibromyalgia

A study in the Oct. 15, 2010 issue of the Journal of Clinical Sleep Medicine found that adults with fibromyalgia had a much higher prevalence and risk of restless legs syndrome than healthy controls. The study suggests that treating RLS may improve sleep and quality of life in people with fibromyalgia.

15 Oct 2010

Yoga exercises may combat fibromyalgia: Research

According to new research conducted at Oregon Health & Science University, yoga exercises may have the power to combat fibromyalgia a medical disorder characterized by chronic widespread pain. The research is being published in the November 10 online edition of the journal Pain and will appear online Thursday, Oct. 14.

14 Oct 2010

Fibromyalgia News and Research

Latest Fibromyalgia News and Research

Pico-Tesla commences placebo-controlled Magneceutical Therapy study for Alzheimer's disease

Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease

New study reports close association between obesity and fibromyalgia

Ramius/RP Group extend tender offer to acquire Cypress Bioscience

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Adeona expands and enhances zinc-based product candidate portfolio

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Depression drug appears effective in reducing pain associated with breast cancer treatment

Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting

FDA grants Impax tentative approval for generic Cymbalta NDA

Adeona third quarter total net revenues increase to $289,898

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

TONIX Pharmaceuticals announces Phase 2a study results of cyclobenzaprine in Fibromyalgia Syndrome

Tai Chi benefits individuals with arthritis

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Study suggests treating RLS may improve sleep and quality of life in people with fibromyalgia

Yoga exercises may combat fibromyalgia: Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Fibromyalgia News and Research

Latest Fibromyalgia News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in